Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation.

ABSTRACT: Advanced-stage sarcomas pose a major challenge in oncology, as they are often resistant to conventional therapies and associated with poor prognosis. CAR-based cellular immunotherapy is emerging as a very promising therapeutic option; however, clinically relevant animal models are urgently needed to accelerate the clinical development of these approaches. B7-H3 molecule, due to its low expression in normal tissue, high prevalence in multiple human cancers, and association with cancer stemness and aggressiveness, represents one of the most attractive targets for CAR-immunotherapy. In this study, we established a preclinical cellular immunotherapy platform based on canine cytokine-induced killer cells (CIK) redirected by an antihuman B7-H3 CAR against canine sarcoma cells and 3D sarcoma sphe

SUBMITTER: De Maria R 

PROVIDER: S-EPMC12433426 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature